Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer Prevention
Researchers at University of Florence, Department of Radiotherapy release new data on breast cancer prevention
February 1st, 2007
Data detailed in "Alternating intravenous and oral vinorelbine plus epirubicin with pegfilgrastim as neoadjuvant treatment of locally advanced breast cancer" have been presented. "In order to downstage locally advanced breast cancer, neoadjuvant chemotherapy consisting of intravenous vinorelbine 25 mg/m plus epirubicin 75 mg/m given on day 1 and oral vinorelbine 60 mg/m on day 8 was administered every 3 weeks for four courses. On day 2, all patients received a single subcutaneous injection of pegfilgrastim (6 mg)," scientists in Florence, Italy report. "From March 2004 to June 2005, 22 patients were enrolled. Patients characteristics were: median age, 53 years (range:...
Source: Women's Health Weekly (2007-02-01)
|
